Abstract

The involvement of cholecystokinin receptors in the phenomenon of satiety has been the impetus for significant research efforts, leading to the design and synthesis of CCK-A selective agonists for the possible treatment of obesity. The Abbott laboratories have described a novel series of pseudotetrapeptides represented by compound A71623, a highly potent and selective peripheral receptor agonist, but possessing very poor bioavailability. Starting from the structural requirements of this series of compounds, a peptidomimetic study was investigated, especially focusing on the N-terminal part of A71623. Using standard coupling methods, introduction of unnatural aromatic amino acids bearing a 2-carboxyethyl side chain on their α-amino group, along with backbone length modulation, afforded selective analogues, presenting a highly modified peptidic backbone. From our two lead compounds, further optimization is under development, tending towards nonpeptidic structures.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call